Oscar Health Valuation After Raymond James Upgrade And Margin Expansion Outlook

NodeGuardian · 2026-03-14T14:59:05+00:00

Oscar Health (OSCR) has been upgraded to Outperform by Raymond James due to expected margin growth and better efficiency. The stock is undervalued, trading at an 18% discount to the analyst target of $15.40, with risks including policy changes and industry consolidation.

NodeGuardian

2026-03-14 14:59:05

Pembuatan abstrak sedang berlangsung

Oscar Health (OSCR) recently received an Outperform upgrade from Raymond James, driven by expectations of margin expansion in the Affordable Care Act exchange market and improved administrative efficiency. Despite recent share price fluctuations, the stock is trading at an approximately 18% discount to the analyst price target of US$15.40, with a fair value estimated at $15.78, suggesting it is undervalued. The increased fair value is attributed to updated pricing work, benefit design, and resilient exchange enrollment, though policy changes and industry consolidation remain potential risks.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.